Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | AKT2 | P31751 | 2/20 | 0.58 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.49 |
| ▸ | STK3 | Q13188 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | MARK3 | P27448 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804847 | 1.00 | HTT (0.58) | HTTLMNAALOX15AKT2MAP3K5 | |
| SCHEMBL9095851 | 0.98 | HTT (0.57) | HTTLMNAALOX15AKT2MAP3K5 | |
| SCHEMBL29804936 | 0.98 | HTT (0.57) | HTTLMNAALOX15AKT2MAP3K5 | |
| SCHEMBL31740761 | 0.95 | HTT (0.53) | HTTLMNAALOX15AKT2MAP3K5 | |
| SCHEMBL6755688 | 0.91 | HTT (0.47) | HTTLMNAALOX15AKT2MAP3K5 | |
| SCHEMBL1030418 | 0.84 | HTR2C (0.58) | HTTLMNAALOX15AKT2MAP3K5 | |
| SCHEMBL13718480 | 0.83 | HRH4 (0.60) | HTTJAK3MAPK1TP53LRRK2 | |
| SCHEMBL29804858 | 0.83 | CHEK1 (0.60) | JAK3MAPK1LRRK2STK3KDM4E | |
| SCHEMBL336612 | 0.83 | CHEK1 (0.60) | JAK3MAPK1LRRK2STK3KDM4E | |
| SCHEMBL1003057 | 0.81 | AKT2 (0.64) | HTTLMNAAKT2JAK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| CN-110191882-A | Novel heterocyclic compounds, preparation method and the pharmaceutical composition comprising it | 株式会社大熊制药 | 2019-08-30 | — | — | CN | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-5574149-A | Method of treating HIV infections with 2',3'-dideoxy-3'-fluoro-5-chlorouridine | GLAXO WELLCOME INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0670328-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-06 | — | — | EP | disclosed |
| EP-0669341-A1 | Therapeutic Nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-08-30 | — | — | EP | disclosed |
| EP-0317128-A2 | Anti-HIV Pyrimidine Nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-24 | — | — | EP | disclosed |
| US-3996361-A | ANTIEDEMATOUS, REDUCING CAPILLARY PERMEABILITY | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | HSP90B1, HSPBP1, HSP90AB2P | HTT 2483/4885LMNA 1466/4885ALOX15 3777/4885 |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | HTT 83/4885LMNA 1533/4885ALOX15 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.